During 2019, 9.28-10.2, 32nd ESICM LIVES was held in Berlin, Germany. More than 6000 doctors, anesthesiologists, nursing staffs and industry representatives attended, and over 300 Internationally renowned experts gave excellent academic reports.

32nd ESICM LIVES opening ceremony 

Start-up meeting of observational trial on cytokine adsorption in Sepsis was held successfully in Berlin. Professor Alexander Kersten, ICU director of the university hospital of Aachen, Germany, who initiated the study, chaired the meeting and gave a detailed report on the clinical trial protocol. Representatives from 12 European and Chinese research institutes from 8 countries, including university hospital London, Vienna medical college, Austria, and university hospital Pavia, Italy, attended the meeting and held a heated discussion, reaching consensus on the content and planning of clinical trials.

Start-up meeting of observational trial on cytokine adsorption in Sepsis

Professor Jean-Louis Vincent, President of the international ICU union, founder of the European ICU society and academician of the Royal Belgian Medical College attended the meeting and made a speech. He discussed the status of Sepsis treatment and the unmet clinical needs, hoping that Jafron's adsorption technology could bring innovative and effective solutions to the clinic.

Jean-Louis Vincent speech: “Unmet clinical needs for sepsis treatment”

Professor Claudio Ronco, founder of the international institute of nephrology in Italy, comprehensively analyzed the clinical benefits and safety of blood purification treatment, especially the Jafron adsorption technology, at the meeting, and placed high expectations on the results of this clinical study.

Claudio Ronco speech: “Adsorption technology commitment”

Mr. Dong fan, Jafron CEO, attended the meeting and made a speech, expressing his support for this medical research and his vision and determination to contribute China's original power to human health.

Jafron CEO Mr. Dong Fan delivered speech

It is believed that the multi-center clinical study on Sepsis in Jafron will provide important evidence-based medical evidence for the application of Hemoperfusion in severe diseases and further guide clinical practice at home and abroad.